Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDMA requests feedback meeting on its research plan for OTC spermicides.

This article was originally published in The Tan Sheet

Executive Summary

FDA DISCUSSION OF SPERMICIDE BIOACTIVITY TESTING for comparisons with the U.S. Pharmacopeial reference standard is requested by the Nonprescription Drug Manufacturers Association in March 3 comments to the agency. NDMA asks for a "feedback" meeting with FDA to discuss several aspects of its proposed research plan to continue OTC availability of spermicides, including appropriate in vitro and in vivo bioactivity testing to be used to compare products with a USP reference standard.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel